NEW YORK, April 15, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding IntercontinentalExchange, Inc. (NYSE: ICE), The Western Union Company (NYSE: WU), Essex Property Trust Inc. (NYSE: ESS), Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Pharmacyclics Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1135-100free.
IntercontinentalExchange, Inc. Analyst Notes
On April 7, 2014, IntercontinentalExchange, Inc. (ICE) provided an update on the first week of trading for Liffe listed 30-Year Ultra Long Gilt futures, which complements Liffe's existing 10-Year Gilt futures and seeks to help participants manage their risk exposure to longer dated UK debt. The contract was launched on March 31, 2014 with strong volumes of 9,214 contracts traded and open interest of 2,634 as on April 4, 2014. Commenting on the development, David Peniket, President and COO, Liffe and ICE Futures Europe said, "We would like to thank UK Gilt market participants for supporting this product launch, which is the first of many new products. The early participation in the Ultra Long Gilt market demonstrates the importance of having a full range of maturities to manage risk in the UK debt markets." The full analyst notes on IntercontinentalExchange are available to download free of charge at:
The Western Union Company Analyst Notes
On April 9, 2014, The Western Union Company (Western Union) announced a film partnership deal with 20th Century Fox for its animated feature RIO 2. According to the Company, the partnership will expand consumer reach for both the companies with a joint global marketing campaign including TV advertising, print, point of sale, online, out-of-home, and social media. Laston Charriez, Western Union, SVP (Marketing), US, commented, "RIO 2 provides a new medium to engage our customers in a fun artistic approach, conveying the intrinsic connection of one's roots with family and loved ones. This theme resonates with the sentiments of our customers, and underscores a brand attribute that Western Union is proud to embody with its global network of services." The full analyst notes on Western Union are available to download free of charge at:
Essex Property Trust Inc. Analyst Notes
On April 8, 2014, Essex Property Trust, Inc. (Essex Property) announced that its operating partnership, Essex Portfolio, L.P., has priced a private placement of $400 million aggregate principal amount of senior unsecured notes (Notes) at an interest rate of 3.875% per annum. The Notes, maturing on May 1, 2024, were priced at 99.234% of par value with a yield to maturity of 3.968%. The offering is expected to close on April 15, 2014 and the interest will be payable semi-annually with first interest payment due November 1, 2014. Essex Portfolio expects to use net proceeds to refinance existing senior unsecured indebtedness and for general corporate purposes. The Notes have been assigned a 'BBB+' credit rating with stable outlook by Fitch Ratings. Essex Property recently became the 18th REIT to join the S&P 500 index, following the completion of its merger with BRE Properties in a $4.3 billion deal. The full analyst notes on Essex Property are available to download free of charge at:
Valeant Pharmaceuticals International, Inc. Analyst Notes
On March 25, 2014, Valeant Pharmaceuticals International, Inc. (Valeant) and Actavis Plc (Actavis) jointly announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). Actavis had acquired the rights to Metronidazole 1.3% from Valeant in April 2013. Under the terms of the agreement, Actavis will pay Valeant up to $57 million in up-front payments, milestone payments and certain guaranteed royalty payments during the first three years of commercialization depending on market conditions. Actavis will also pay ongoing royalties to Valeant after the first three years of commercialization. Tage Ramakrishna, M.D. and CMO, Valeant, said, "Valeant is pleased that another internal R&D compound has been approved by the FDA and will soon be available." The full analyst notes on Valeant are available to download free of charge at:
Pharmacyclics Inc. Analyst Notes
On April 8, 2014, Pharmacyclics, Inc. (Pharmacyclics) announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), based on data from the randomized, multi-center, open-label Phase III RESONATETM study, PCYC-1112, a head-to-head comparison of single agent IMBRUVICATM (ibrutinib) versus ofatumumab in 391 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who had received at least one prior therapy. According to the Company, IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc. Bob Duggan, CEO and Chairman of the Board, Pharmacyclics, said, "This supplemental new drug application in previously treated CLL patients is our first Phase III submission to the FDA seeking full approval for the use of IMBRUVICA." The full analyst notes on Pharmacyclics are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. This release was produced by first_testproducer last_testproducer, a CFA charter-holder and reviewed by Ananya Ghosh, a CFA charter-holder. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Please visit http://www.analystsreview.com/disclaimer for our full legal disclaimer. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review